Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2008 May 19;3(5):10.1371/annotation/eaf9794a-9325-4977-952d-51285c3f6c6a. doi: 10.1371/annotation/eaf9794a-9325-4977-952d-51285c3f6c6a

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy

Tal I Arnon, Gal Markel, Ahuva Bar-Ilan, Jacob Hanna, Eyal Fima, Fabrice Benchetrit, Ruth Galili, Adelheid Cerwenka, Daniel Benharroch, Netta Sion-Vardy, Angel Porgador, Ofer Mandelboim
PMCID: PMC2637116

The funding information for this paper is missing. It should read:

This work was supported by the Israel Science Foundation (O.M.), the Binational Science Foundation (O.M.), the AICR (O.M), the ICRF (O.M.), the European Commission (LSHC-CT-2002-518178 and MRTN-CT-2005 to O.M.), the Israel Ministry of Health (A.P.), the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ), and Israeli's Ministry of Science and Technology (MOST) (A.P.).


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES